PUBLIKATIONSLISTE. Priv.Doz.Dr.med. Birgit Grünberger. 44 Originalarbeiten 4 letters 2 case reports 1 review 3 Buchbeiträge 64 publizierte Abstracts

Transkript

1 PUBLIKATIONSLISTE Priv.Doz.Dr.med. Birgit Grünberger 44 Originalarbeiten 4 letters 2 case reports 1 review 3 Buchbeiträge 64 publizierte Abstracts Krankenhaus der Barmherzigen Brüder Medizinische Abteilung Johannes-von-Gott-Platz 1/ Wien Tel : / birgit.gruenberger@bbwien.at

2 PAPERS 1. CETUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH UNRESECTABLE ADVANCED OR METASTATIC BILIARY TRACT CANCER: A PHASE 2 STUDY Birgit Gruenberger, Johannes Schueller, Ute Heubrandtner, Fritz Wrba, Dietmar Tamandl, Klaus Kaczirek, Rudolf Roka, Sandra Freimann-Pircher, and Thomas Gruenberger Lancet Oncology, 2010 Dec;11(12): Epub 2010 Nov 9 IF: 14, IMPORTANCE OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN POTENTIALLY CURABLE COLORECTAL CANCER LIVER METASTASES Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D and Gruenberger BMC Cancer, 2008 Apr 25;8:120. IF: 3, BEVACIZUMAB, CAPECITABINE AND OXALIPLATIN AS NEOADJUVANT THERAPY FOR PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski, Herbst F, Gruenberger T J Clin Oncol Apr 10;26(11): IF: 17, USING BEVACIZUMAB AND CETUXIMAB BEFORE LIVER SURGERY Gruenberger B, Gruenberger T Current Colorectal Cancer Reports ASSESSMENT OF THE ROLE OF HEPATITIS C, HELICOBACTER PYLORI AND AUTOIMMUNITY IN MALT LYMPHOMA OF THE OCULAR ADNEXE IN 45 AUSTRIAN PATIENTS Gruenberger B, Woehrer S, Troch M, Hauff W, Lukas J, Streubel B, Muellauer L, Chott A, Raderer M. Acta Oncol Oct 22;1-5 IF: 2, PALLIATIVE CHEMOTHERAPY FOR RECURRENT AND METASTATIC ESOPHAGEAL CANCER Grünberger B, Raderer M, Schmidinger M, Hejna M. Anticancer Res Jul-Aug;27(4C): Review 7. ANTIBIOTIC TREATMENT IS NOT EFFECTIV IN PATIENTS INFECTED WITH HELICOBATCER PYLORI SUFFERING FROM EXTRAGASTRIC MUCOSE- ASSOCIATED LYMPHIOD TISSUE LYMPHOMA Gruenberger B, Woehrer S, Streubel B, Formanek M, Petkov V, Puespoek A, Haefner M, Hejna M, Jaeger U, Chott A and Raderer J Clin Oncol 2006, 24 (9): IF: 17,157

3 8. BLIND ANTIBIOTIC TREATMENT TARGETING CHLAMYDIA IS NOT EFFECTIVE IN PATIENTS WITH MALT LYMPHOMA OF THE OCULAR ADNEXA Grünberger B, Hauff W, Lukas J, Wöhrer S, Zielinski Z, Streubel B, Chott A and Raderer M Ann Oncol 2006,17: IF: 4, HER-2 NEU PROTEIN EXPRESSION IN COLORECTAL CANCER Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch and Wrba F BMC Cancer 2006, 6; 123 IF: 3, SIDE EFFECTS DURING CHEMOTHERAPY PREDICT TUMOR RESPONSE IN ADVANCED COLORECTAL CANCER B. Schuell, T. Gruenberger, G.V. Kornek, N. Dworan, D. Depisch, F. Lang, B. Schneeweiss and W. Scheithauer Br J Cancer 2005; 93, IF: 4, EFFECTIVE COMBINATION CHEMOTHERAPY WITH BIMONTHLY DOCETAXEL AND CISPLATIN + HEMATOPOETIC GROWTH FACTOR SUPPORT IN PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER Schüll B, Kornek GV, Schmid K, Raderer M, Hejna M, Lenauer A, Depisch D, Lang F and Scheithauer W Oncology 2003; 65(3):211-7 IF: 1, CAPECITABINE AS SALVAGE THERAPY FOR BREAST CANCER PATIENTS WITH EXTENSIVE LIVER METASTASES AND ASSOCIATED IMPAIRMENT OF LIVER FUNCTION Schüll B, Scheithauer W, Kornek GV Onkologie 2003 Dec; 26(6):578-80; Case report 13.IDIOSYNCRATIC REACTION AFTER OXALIPLATIN: CIRCUMVENTION BY USE OF A CONTINOUS INFUSIONAL ADMINISTRATION SCHEDUL Schüll B, Kornek GV, Scheithauer W Ann Oncol 2001; 12: ; Case report 14.RALTITREXED UND OXALIPLATIN BEIM KOLOREKATLEN KARZINOM: IN VITRO UND IN VIVO UNTERSUCHUNG EINER SYNERGISTISCH WIRKSAMEN ZYTOSTATIKAKOMBINATION Schüll B, Scheithauer W Acta medica austriaca 2002;29: IF: +1,5 (Dissertation) 15.SECOND LINE TREATMENT OF ADVANCED COLORECTAL CANCER WITH A BIWEEKLY OXALIPLATIN PLUS IRINOTECAN COMBINATION THERAPY Schüll B, Kornek G.V., Schmid K, Raderer M, Ulrich-Pur H, Fiebiger W, Schneeweiss B, Lenauer A, Depisch D and Scheithauer W Onkologie 2002;25: IF: 1,545

4 16.HEPATIC ARTERIAL CHEMOTHERAPY FOR LIVER METASTASES FROM COLORECTAL CANCER : TREATMENT RESULTS, LIMITATIONS & FUTURE ASPECTS Schüll B, Scheithauer W Eur Surg 2002;34: SINUSOIDAL OBSTRUCTION SYNDROME IMPAIRS LONG-TERM OUTCOME OF COLORECTAL LIVER METASTASES TREATED WITH RESECTION AFTER NEOADJUVANT CHEMOTHERAPY. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, Gruenberger T. Ann Surg Oncol Feb;18(2): Epub 2010 Sep 16. IF= 4, PLASMA DISPOSITION OF CAPECITABINE AND ITS METABOLITES 5'DFCR AND 5'DFUR IN A STANDARD AND DOSE-INTENSIFIED MONOTHERAPY REGIMEN. Czejka M, Schueller J, Farkouh A, Gruenberger B, Scheithauer W. Cancer Chemother Pharmacol Mar;67(3): Epub 2010 May 22. IF= 2, BEVACIZUMAB IMPROVES PATHOLOGICAL RESPONSE OF COLORECTAL CANCER LIVER METASTASES TREATED WITH XELOX/FOLFOX. Klinger M, Tamandl D, Eipeldauer S, Hacker S, Herberger B, Kaczirek K, Dorfmeister M, Gruenberger B, Gruenberger T. Ann Surg Oncol Aug;17(8): Epub 2010 Feb 23. IF= 4, LIVER RESECTION REMAINS A SAFE PROCEDURE AFTER NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB: A CASE-CONTROLLED STUDY. Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K, Fleischmann E, Gruenberger T. Ann Surg Jul;252(1): IF= 7,9 21. PHARMACOKINETICS OF IRINOTECAN IN COMBINATION WITH BIWEEKLY CETUXIMAB IN PATIENTS WITH ADVANCED COLORECTAL CANCER. Czejka M, Gruenberger B, Kiss A, Farkouh A, Schueller J. Anticancer Res Jun;30(6): IF= 1, THROMBOSPONDIN-1: A UNIQUE MARKER TO IDENTIFY IN VITRO PLATELET ACTIVATION WHEN MONITORING IN VIVO PROCESSES P. Starlinger, H. P. Moll, A.Assinger, C.Nemeth, K. Hoetzenecker, B.Gruenberger, T. Gruenberger, I. Kuehrer, S. F. Schoppmann, M. Gnant and C. Brostjan Journal of Thrombosis and Haemostasis, 2010 Aug;8(8): doi: /j x. Epub 2010 May 12. IF=6.069

5 23. LYMPH NODE RATIO AFTER CURATIVE SURGERY AFTER INTRAHEPATIC CHOLANGIOCARCINOMA Tamandl D, Kaczirek K, Gruenberger B, Koelblinger C, Maresch J, Jakesz R and Gruenberger T British Journal of Surgery 2009; 96: IF: 4, SYSTEMIC BEVACIZUMAB (AVASTIN) THERAPY FOR EXUDATIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. THE BEAT-AMD- STUDY K E Schmid-Kubista, I Krebs, B Gruenberger, F Zeiler, J Schueller and S Binder Br.J. Opthalmology 2009;93; IF:2, BEVACIZUMAB PROTECTS AGAINST SINUSOIDAL OBSTRUCTION SYNDROME AND DOES NOT INCREASE RESPONSE RATE IN NEOADJUVANT XELOX/FOLFOX THERAPY OF COLORECTAL CANCER LIVER METASTASES Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, Koelblinger C, Gruenberger B, Gruenberger T. Eur J Surg Oncol May;35(5): IF: 2, SURGERY AFTER NEOADJUVANT CHEMOTHERAPY FOR COLORECTAL LIVER METASTASES IS SAFE AND FEASIBLE IN EDERLY PATIENTS Tamandl D, Gruenberger B, Herberger B, Kaczirek K, Gruenberger T. J Surg Oncol Oct 1;100(5): IF: 2, INFLUENCE OF HEPATIC RESECTIN MARGIN ON RECURRENCE AND SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T Ann Surg Oncol Oct;15(10): IF: 3, PATTERNS OF HEPATOTOXICITY AFTER CHEMOTHERAPY FOR COLORECTAL CANCER LIVER METASTASES Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T Eur J Surg Oncol 2008, Feb 11 IF: 2, NEOADJUVANT TREATMENT OF COLORECTAL CANCER WITH BEVACIZUMAB: THE PERIOPERATIVE ANGIOGENIC BALANCE IS SENSITIVE TO SYSTEMIC THROMOSPONDIN-1 LEVELS Brostjan C, Gebhardt K, Gruenberger B, Steinrueck C, Zommer H, Freudenthaler H, Roka S and Gruenberger T Clin Cancer Res 2008 Apr 1;14(7): IF: 6, SELECTIVE RESECTION OF COLORECTAL LIVER METASTASES Tamandl D, Gruenberger B, Herberger B, Schoppmann S, Bodingbauer M, Schindl M, Puhalla H, Fleischmann E, Schima W, Jakesz R, Laengle F, Gruenberger T Eur J Surg Oncol 2007; 33:174-82

6 31. ADEQUATE PREOPERATIVE STAGING RARELY LEADS TO A CHANGE OF INTRAOPERATIVE STRATEGY IN PATIENTS UNDERGOING SURGERY FOR COLORECTAL CANCER LIVER METASTASES D. Tamandl, B. Herberger, B. Gruenberger, S. Schoppmann, H. Puhalla, M. Schindl, W. Schima, R. Jakesz, Th. Gruenberger Surgery 2008, May;143(5): IF: 3, ACTIVATED MAMMALIAN TARGET OF RAPAMYCIN IS AN ADVERSE PROGNOSTIC FACTOR IN PATEINTS WITH BILIARY TRACT ADENOCARCINOMA Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M. Clin Cancer Res Aug 15;13(16): IF: 6, NEOADJUVANT THERAPY WITH BEVACIZUMAB Gruenberger T, Gruenberger B and Scheithauer W J Clin Oncol 2006, 24: letter 34. BEVACIZUMAB IS ACTIVE IN MALIGNANT EFFUSION Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Ann Oncol 2006; 17; 1853, letter 35. INTERDISCIPLINARY MANAGEMENT OF COLORECTAL CANCER LIVER METASTASES Th. Grünberger, B. Grünberger, A. Becherer, J. Kettenbach, K. Dieckmann, W. Schima Eur Surg 2006; 38: TREATMENT AND OUTCOME OF INTRAHEPATIC CHOLANGIOCELLULAR CARCINOMA Puhalla H, Schüll B, Pokorny H, Kornek GV, Scheithauer W, Gruenberger T Am J Surg 2005, 189/2;173-7 IF: 2, CHANGES IN LIVER SURGERY FOR COLORECTAL CANCER LIVER METASTASES UNDER NEOADJUVANT TREATMENT STRATEGIES Gruenberger T, Schüll B, Puhalla H, Schwanzer E, Bodingbauer M, Laengle F, Kornek G, ScheithauerW Eur Surg 2004, 36(5), MITOMYCIN C IN COMBINATION WITH CAPECITABINE OR BIWEEKLY HIGH DOSE GEMCITABINE IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER: A RANDOMIZED PHASE II TRIAL Kornek GV, Schüll B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F, Scheithauer W Ann Oncol 2004 Mar;15(3): IF: 4, BIWEEKLY HIGH-DOSE GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA: A RANDOMIZED PHASE II TRIAL

7 Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek GV Ann Oncol 2003 Jan;14(1): IF: 4, RANDOMIZED MULTICENTER PHASE II TRIAL OF TWO DIFFERENT SCHEDULES OF CAPECITABINE PLUS OXALIPLATIN AS FIRST LINE TREATMENT IN ADVANCED COLORECTAL CANCER Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, Schneeweiss B, Lang F, Lenauer A and Depisch D J Clin Oncol 2003 Apr 1;21(7): IF: 17, IRINOTECAN PLUS RALTITREXED VERSUS RALTITREXED ALONE IN PATIENTS WITH GEMCITABINE-PRETREATED ADVANCED PANCREATIC ADENOCARCINOMA Ulrich-Pur H, Raderer M, Kornek GV, Schüll B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F and Scheithauer W Br J Cancer 2003 Apr22;88(8): IF: 4, SECOND-LINE TREATMENT OF ADVANCED GASTRIC CANCER WITH OXALIPLATIN PLUS RALTITREXED Schmid K, Kornek GV, Schüll B, Raderer M, Lenauer A, Depisch D, Lang F, Scheithauer W Onkologie 2003 Jun; 26(3): IF: 1, INTERMITTENT WEEKLY HIGH-DOSE CAPECITABINE IN COMBINATION WITH OXALIPLATIN: A PHASE I/II STUDY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Längle F and Huber H Ann Oncol 2002 Oct;13(10): IF: 4, EFFECTIVE TREATMENT OF OXALIPLATIN-INDUCED CUMULATIVE POLYNEUROPATHY WITH ALPHA-LIPOIC ACID Gedlicka C, Scheithauer W, Schüll B, Kornek GV J Clin Oncol 2002 Aug 1;20(15): , letter 45. EFFECTIVE COMBINATION CHEMOTHERAPY WITH PACLITAXEL AND CISPLATIN WITH OR WITHOUT G-CSF AND/OR ERYTHROPOIETIN IN PATIENTS WITH ADVANCED GASTRIC CANCER Kornek GV, Raderer M, Schüll B, Fiebiger W, Gedlicka C, Lenauer A, Depisch D, Schneeweiss B, Lang F, Scheithauer W Brit J Cancer 2002; 86: IF: MITOXANTRON AND CISPLATIN IN RECURRENT AND/OR METASTATIC SALIVERY GLAND MALIGNANCIES Gedlicka C, Schüll B, Formanek M, Kornfehl J, Burian M, Knerer B, Selzer E, Scheithauer W, Kornek GV Anti-Cancer Drugs 2002 Jun; 13(5):491-5

8 IF: 2, RANDOMIZED MULTICENTER PHASE II TRIAL OF OXALIPLATIN PLUS IRINOTECAN VERSUS RALTITREXED AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER Scheithauer W, Kornek GV, Raderer M, Fiebiger W, Gedlicka C, Schüll B, Brugger S, Lang F, Lenauer A, and Depisch J Clin Oncology 2002; 20: ,2002 IF: 17, TREATMENT OF ADVANCED BREAST CANCER WITH DOCETAXEL AND GEMCITABINE ± HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR Kornek GV, Haider K, Kwasny W, Raderer M, Schüll B, Payrits T, Depisch D, Kovats E, Lang F, Scheithauer W Clinical Cancer Research 2002 May: 8(5): IF: 6, TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WITH BIWEEKLY HIGH-DOSE GEMCITABINE Ulrich-Pur H, Kornek GV, Fiebiger W, Schüll B, Raderer M, Scheithauer W Oncology 2001 Jun;60(4): IF: 1, SECOND LINE TREATMENT WITH OXALIPLATIN + RALTITREXED IN PATIENTS WITH ADVANCED COLORECTAL CANCER FAILING FLUOROPYRIMIDINE/ LEUCOVORIN BASED CHEMOTHERAPY Scheithauer W, Kornek GV, Schüll B, Ulrich-Pur H, Fiebiger W, Raderer M, Lang F, Schneeweiss B, Lenauer A, Depisch D Ann Oncol 2001; 12: IF: 4, IMPACT OF HEMOGLOBIN LEVEL AND USE OF RECOMBINANT ERYTHROPOETIN ON EFFICACY PREOPERATIVE CHEMO-RADIATION THERAPY FOR SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F, Selzer E, Lavey RS Int J Radiat Oncol Biol Phys 2001 Jul 1;50(3): IF: 4, OXALIPLATIN-INDUCED FEVER AND RELEASE OF IL-6 Ulrich-Pur H, Fiebiger WC, Schüll B, Kornek GV, Scheithauer W, Raderer M Oncology 2000 Sep;59(3).187-9, letter

9 DISSERTATION RALTITREXED UND OXALIPLATIN BEIM KOLOTEKTALEN KARZINOM: IN VITRO UND IN VIVO UNTERSUCHUNGEN EINER SYNERGISTISCH WIRKSAMEN ZYTOSTATIKAKOMBINATION Betreuung und Erstbegutachter: Ao. Univ. Prof. Dr. Werner Scheithauer Begutachter: Ao. Univ. Prof. Dr. Gerhard Hamilton BUCHBEITRÄGE 1. CHIRURSCHE THERAPIE COLORECTALER LEBERMETASTASEN Gruenberger Th, Gruenberger B In: Tumorchirurgie Strategien und Standards für die Praxis, Springer Verlag 2007; in press 2. COLORECTAL CANCER LIVER METASTASES: NEOADJUVANT THERAPY WITH BEVACIZUMAB Gruenberger Th, Gruenberger B In: Methods of Cancer Diagnosis, Therapy and Prognosis; Springer Verlag 2007; in press 3. SYSTEMISCHE CHEMOTHERAPIE BEI KOLOREKTALEN LEBERMETASTASEN: NEOADJUVANT, ADJUVANT UND PALLIATIV Grünberger B. In: Therapiemanagement von Lebermetastasen von Gastrointestinalen Tumoren; Uni-Med Verlag; in press PREISE 1. BEST ABSTRACT Frühjahrstagung 2008 der österr. Gesellschaft für Hämatologie und Onkologie Für: Progression-free survival in a phase II study of perioperative Bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer Grünberger B et al. ABSTRACTS & POSTER & VORTRÄGE 1. IFOSFAMIDE AND NOVANTRON IN THE TREATMENT OF RECURRENT AND/OR METASTATIC SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK (HNSCC) Schüll B, Glaser C, Millesi W, Ulrich-Pur H, Kornfehl J, Burian M, Formanek M, Toth J, KornekGV Frühjahrstagung 2000 der Österreichischen Gesellschaft für Hämatologie und Onkologie

10 2. R-HuERYTHROPOETIN TREATMENT INCREASES EFFICACY OF NEO- ADJUVANT RADIOCHEMOTHERAPY AND IMPROVES CANCER FREE SURVIVAL OF PATIENTS WITH ORAL SQUAMOUS CELL CARCINOMA Glaser C, Millesi W, Wanschitz F, Schüll B, Lang S, Leitha T, Kornek GV ACSO Vol.18:1543 Atlanta Mai R-HuERYTHROPOETIN SUPPLY INCREASES EFFICACY OF NEOADJUVANT RADIOCHEMOTHERAPIE IN PATIENTS WITH ORAL SQUAMOUS CARCINOMA Glaser C, Millesi W, Gössweiner S, Leitha T, Schüll B, Ewers R, Lang S 14 th International Conference on oral and Maxillofacial Surgery in Washington DC, USA April MULTICENTER PHASE II TRIAL OF DOSE-FRACTIONATED IRINOTECAN IN PATIENTS WITH ADVANCED COLORECTAL CANCER FAILING OXALIPLATIN- BASED FIRST-LINE COMBINATION CHEMOTHERAPY Fiebiger W, Ulrich-Pur H, Kornek GV, Raderer M, Gedlicka G, Schüll B, Depisch D, Lang F, Pidlich J, Scheithauer W Frühjahrstagung 2001 der Österr. Gesellschaft für Hämatologie und Onkologie, Pörtschach 5. GEMCITABINE PLUS CAPECITABINE: AN EFFECTIVE DRUG COMBINATION FOR ADVANCED PANCREATIC ADENOCARCINOMA Ulrich-Pur H, Kornek GV, Raderer M, Fiebiger W, Gedlicka G, Schüll B, Depisch D, Lang F, Schneeweiss B, Scheithauer W Frühjahrstagung 2001 der Österr. Gesellschaft für Hämatologie und Onkologie, Pörtschach 6. TREATMENT OF ADVANCED GASTRIC CANCER WITH PACLITAXEL AND CISPLATIN + HEMATOPOETIC GROWTH FACTOR SUPPORT Penz M, Raderer M, Kornek GV, Fiebiger W, Ulrich-Pur H, Schüll B, Scheithauer W Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für Hämatologie und Onkologie; Graz Oktober PALLIATIVE CHEMOTHERAPIE DES KOLOREKATLEN KARZINOMS MIT TOMUDEX UND OXALIPLATIN Schüll B, Kornek GV, Ulrich-Pur H, Penz M, Fiebiger W, Raderer M, Haider K, Kwasny W, Depisch D, Scheithauer W Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaft für Hämatologie und Onkologie; Graz Oktober TREATMENT OF ADVANCED BREAST CANCER WITH DOCETAXEL AND GEMCITABINE + HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR Kornek GV, Fiebiger W, Raderer M, Gedlicka C, Schüll B, Haider K, Kwasny W, Depisch D, Scheithauer W Frühjahrstagung 2001 der Österr. Gesellschaft für Hämatologie und Onkologie, Pörtschach 9. IRINOTECAN PLUS OXALIPLATIN IN ADVANCED COLORECTAL CANCER: A RANDOMIZED PHASE II STUDY Ulrich-Pur H, Kornek GV, Raderer M, Fiebiger C, Schüll B, Scheithauer W Third International Conference: Perspectives in Colorectal Cancer, Dublin, June RANDOMIZED MULTICENTER PHASE II TRIAL OF OXALIPLATIN PLUS IRINOTECAN VERSUS RALTITREXED AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER

11 Schüll B, Kornek GV, Raderer M, Fiebiger W, Gedlicka G, Ulrich-Pur H, Brugger S, Schneeweiss B, Lang F, Lenauer A, Depisch D, Scheithauer W Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaft für Hämatologie und Onkologie 2001; Mannheim 30 Sept- 3 Okt 11.DOCETAXEL PLUS CISPLATIN ± GRANULOCYTE COLONY-STIMULATING FACTOR AND/OR ERYTHROPOIETIN IN PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER Schüll B, Kornek GV, Schmid K, Raderer M, Ulrich-Pur H, Haider K, Kwasny W, Depisch D, Lang F, Hejna M, Scheithauer W Frühjahrstagung 2002 der ÖGHO; Linz April BIWEEKLY HIGH-DOSE GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH METASTATIC ADENOCARCINOM: A RANDOMIZED PHASE II TRIAL Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Kornek G Symposium on gastrointestinal, liver and pancreatic cancer, Venice, June 6-8, INTERMITTENT WEEKLY HIGH-.DOSE CAPECITABINE IN COMBINATION WITH OXALIPLATIN: A PHASE I/II STUDY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER Kornek GV, Schüll B, Schmid K, Raderer M, Längle F, Scheithauer W Symposium on gastrointestinal, liver and pancreatic cancer, Venice, June 6-8, BIWEEKLY HIGH DOSE GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC ADENO CARCINOMA: A RANDOMIZED MULTICENTER PHASE II TRIAL Kornek GV, Schüll B, Ulrich-Pur H, Raderer M, Schmid K, Schneeweiss B, Lang F, Haider K, Kwasny W, Depisch D, Scheithauer 12 th International Congress on Anti-Cancer Treatment, Febr. 4 th -7 th, INTERMITTENT WEEKLY HIGH-DOSE CAPECITABINE IN COMBINATION WITH OXALIPLATIN: A PHASE I/II STUDY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Längle F, Huber H 12 th International Congress on Anti-Cancer Treatment, Febr. 4-7, TREATMENT OF ADVANCED BREAST CANCER WITH DOCETAXEL AND GEMCITABINE ± HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR Haider K, Kornek GV, Fiebiger W, Raderer M, Gedlicka C, Schüll B, Kwasny W, Depisch D, Scheithauer W. 18. Jahrestagung der österr. Gesellschaft für Senologie, Toscana Congress Gmunden, Oktober GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA Scheithauer W, Schüll B, Ulrich-Pur H, Schmid K, Raderer M, Lang F, Haider K, Kwasny W 38 annual meeting, ASCO, May,2002

12 18.BIWEEKLY DOCETAXEL PLUS CISPLATIN +/- HUMAN GRANULOCYTE COLONY STIMULATING FACTOR AND/ OR ERYTHROPOETIN IN PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER Schüll B, Kornek GV, Raderer M, Dworan N, Haider K, Kwasny K, Depisch D, Lang F, Hejna M, Scheithauer W ÖGHO 2002, München 19.PALLIATIVE CHEMOTHERAPIE MIT ORALEM ETOPOSID IN VORBEHANDELTEN PATIENTEN MIT FORTGESCHRITTENEM KOPF-HALS MALIGNOM Gedlicka G, Schüll B, Formanek M, Kornfehl J, Ramberger P, Burian M, Kornek GV 46. Österr. HNO-Kongreß MITOMYCIN C IN COMBINATION WITH CAPTECITABINE OR BIWEELÖY HIGH DOSE GEMCITABINE IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER: PRELIMINARY RESULTS OF PARALLEL PHASE II TRIAL Kornek GV, Schmid K, Schüll B, Raderer M, Kwasny W, Haider K, Depisch D, Friedrich L, Scheithauer W 27 th ESMO Congress Oct 2002, Nice,France 21.GEMCITABINE ALONE OR IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED PANCREATIC ADENOCARCINOMA Scheithauer W, Schüll B, Ulrich Pur H, Schmid K, Raderer M, Lang F, Haider K, Kwasny W 38 th ASCO 2002, Orlando, Florida 22.MITOMYCIN C IN COMBINATION WITH CAPTECITABINE OR BIWEEKLY HIGH DOSE GEMCITABINE IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER Scheithauer W, Schüll B, Dworan N, Laengle F, Gruenberger T, Penz M, Haider K, Depisch D, Lang F, Kornek G ASCO Proceedings 2003; 22: NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE COLORECTAL LIVER METASTASES: IMPACT ON LIVER RESECTION Gruenberger T, Schuell B, Kornek G, Scheithauer W HBP 2004, 6/Suppl 1, 109 (Abstract 1186) 24.INTRAHEPATIC CHOLANGIOCELLULAR CARCINOMA: POSSIBLE BENEFIT OF A MULTIDISCIPLINARY APPROACH Gruenberger T, Puhalla H, Schuell B, Kornek GV, Scheithauer W HPB 2004, 6/Suppl 1 (abstract 1187) 25.NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE COLORECTAL LIVER METASTASES: IMPACT ON LIVER RESECTION AND SURVIVAL Gruenberger T, Schuell B, Kornek GV, Scheithauer W Proceedings Am Soc Clin Oncol 2004; 23,270 (Abstract 3598) 26.NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE COLORECTAL LIVER METASTASES: IMPACT ON LIVER RESECTION AND SURVIVAL Gruenberger T, Schuell B, Kornek GV, Scheithauer W Posterpräsentation Gastrointestinal Cancer-Meeting Barcelona, DAS INTRAHEPATISCHE CHOLANGIOZELLULÄRE KARZINOM: VORTEILE INTER MULTIDISZIPLINÄREN THERAPIE Puhalla H, Schüll B, Längle F, Kornek GV, Scheithauer W, Gruenberger T European Surgery 2004; 36/Suppl 198,62

13 28.DO SIDE EFFECTS DURING CHEMOTHERAPY PREDICT TUMOR RESPONSE IN ADVANCED COLORECTAL CARCINOMA? Schüll B, Grünberger T, Kornek GV, Dworan N, Scheithauer W Ann. Oncology 2004; 15 (Suppl. 3), ii90 29.DO SIDE EFFECTS DURING CHEMOTHERAPY PREDICT TUMOR RESPONSE IN ADVANCED COLORECTAL CARCINOMA? Schüll B, Grünberger T, Kornek GV, Dworan N, Scheithauer W Onkologie 2004; 27(Suppl. 3) NEOADJUVANT CHEMOTHERAPY IN PRIMARY RESECTABLE COLORECTAL CANCER LIVER METASTASES Th. Gruenberger, B. Schuell, G. Kornek, W. Scheithauer Ann. Oncology 2004, 15 (Suppl. 3), ii97 31.ELDERLY PATIENTS DO BENEFIT FROM OXALIPLATIN-BASED NEOADJUVANT CHEMOTHERAPY IN RESECTABLE COLORECTAL CANCER LIVER METASTASES Th. Gruenberger, B. Schuell, G. Kornek, W. Scheithauer Proc. Am. Soc. Clinical Oncology 2005; 23/16S,271s(Abstract 3601) 32.HER 2/NEU RECEPTOR EXPRESSION IN COLORECTAL CANCER B. Schuell, T. Gruenberger, W. Scheithauer, Ch. Zielinski, F. Wrba World of Gastrointestinal Cancer, Barcelona, June ANTIBIOTIC TREATMENT IS NOT EFFECTIVE IN PATIENTS WITH EXTRAGASTRIC MALT LYMPHOMA INFECTED WITH HELICOBACTER PYLORI B. Grünberger, S. Wöhrer, B. Streubel, M. Formanek, V. Petkov, A. Püspök, M. Häfner, M.Hejna, U. Jäger, A. Chott, M. Raderer DÖGHO 2005 Hannover 34.VEGF-A EXPRESSION IN PERITONEAL OR PLEURAL EFFUSIONS WITH OR WITHOUT MALIGNANCIES B. Gruenberger, O. Pichlmayer, P. Valent, Th. Gruenberger, M. Krauth, R. Bauer, C. Zielinski, M. Raderer DÖGHO VEGF-A EXPRESSION IN PERITONEAL OR PLEURAL EFFUSIONS WITH OR WITHOUT MALIGNANCIES B. Gruenberger, O. Pichlmayer, P. Valent, Th. Gruenberger, M. Krauth, R. Bauer, C. Zielinski, M. Raderer Ann Oncology 2006; 17(Supp 9): ix68 36.BEVACIZUMAB PLUS XELOX AS NEOADJUVANT THERAPY FOR PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER Th. Gruenberger, D. Tamandl, F. Herbst, W. Scheithauer, C. Zielinski, B. Gruenberger Ann Oncology 2006; 17(Supp 9): ix PROLONGED RECURRENCE-FREE SURVIVAL AFTER NEOADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER LIVER METASTASES Gruenberger Th, Gruenberger B, Tamandl D, Scheithauer W HPB 2006; 8(Supp 2): 125

14 38.IMPACT OF LYMPHANGIOGENESIS IN COLORECTAL LIVER METASTASES S. Schoppmann, A. Fenzl, D. Tamandl, M. Bodingbauer, M. Schindl, H. Puhalla, B. Gruenberger, B. Teleky, T. Gruenberger, F. Längle Ann Oncology 2006; 17(Supp 6): vi33 39.NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER B. Gruenberger, W. Scheithauer, D. Tamandl, H. Puhalla, G. Kornek, C. Zielinski, Th. Gruenberger Ann Oncology 2006; 17(Supp 6): vi39 40.SAFE SURGERY FOR COLORECTAL CACER LIVER METASTASES USING MODERN DISSECTION TECHNIQUES D. Tamandl, B. Gruenberger, B. Herberger, S. Schoppmann, M. Bodingbauer, E. Fleischmann, W. Schima, R. Jakesz, F. Laengle, Th. Gruenberger Ann Oncology 2006; 17(Supp 6): vi57 41.RESECTION OF COLORECTAL LIVER METASTASES UNDER THE ASPECT OF MODERN DISSECTION TECHNIQUES D. Tamandl, B. Gruenberger, B. Herberger, S. Schoppmann, M. Bodingbauer, R. Jakesz, F. Längle, Th. Gruenberger European Surgery 2006; 38/Suppl 209, IMPACT OF LYMPHANGIOGENESIS IN COLORECTAL LIVER METASTASES SF Schoppmann, A. Fenzl, D. Tamandl, M. Bodingbauer, M. Schindl, B. Herberger, E. Schwanzer, H. Puhalla, B. Gruenberger, B. Teleky, Th. Gruenberger, F. Längle European Surgery 2006; 38/Suppl 209, NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER B. Gruenberger, W. Scheithauer, D. Tamandl, H. Puhalla, G. Kornek, C. Zielinski, T. Gruenberger JCO 2006; 24: 157 (suppl, Abstract 3546) 44.BEVACIZUMAB PLUS XELOX AS NEOADJUVANT THERAPY FOR PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER T. Gruenberger, D. Tamandl, H. Puhalla, W. Scheithauer, C. Zielinski, B. Gruenberger Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement),2007: EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN PATIENTS WITH RESECTABLE COLORCTAL CANCER LIVER METASTASES B. Gruenberger, W. Scheithauer, D. Tamandl, C. Zielinski, J. Schueller,T. Gruenberger Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: EFFECTIVITY OF NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORCTAL CANCER B. Gruenberger, W. Scheithauer, D. Tamandl, C. Zielinski, J. Schueller, T. Gruenberger Ann Oncology, 2007, 18 (Supplement 7): vii 76

15 47.NEOADJUVANT BEVACIZUMAB PLUS XELOX IS FEASIBLE IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER RECEIVING SYNCHRONOUS RESECTION B. Gruenberger, W. Scheithauer, D. Tamandl, C. Zielinski, J. Schueller, T. Gruenberger EJC 2007, 5 (4, Supplement): INFLUENCE OF BEVACIZUMAB (BEV) ON PHARMAKOKINETICS (PK) AND METABOLISM OF CAPECITABINE (CAPE) IN METASTATIC COLORECTAL CANCER (MCRC) J. Schueller, M. Czejka, A. Farkouh, K. Aigner, E. Krexner and B. Gruenberger Gastrointestinal Cancer Symposium, 2008, DOES DOSE ESCALATION OF CAPECITABINE (CAPE) INFLUENCE ITS METABOLIC CONVERSION IN METASTATIC COLORECTAL CANCER PATIENTS (MCRC)? J. Schueller, M. Czejka, A. Farkouh, D. Ettlinger, E. Krexner, B. Gruenberger Gastrointestinal Cancer Symposium, 2008, PROGRESSION-FREE SURVIVAL IN A PHASE II STUDY OF PERIOPERATIVE BEVACIZUMAB PLUS XELOX IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER B. Grünberger, K. Kaczirek, J. Schüller, M. Bergmann, C. Zielinski, K. Aigner, T. Grünberger Frühjahrstagung 2008 der österr. Gesellschaft für Hämatologie und Onkologie 51.SYSTEMIC BEVACIZUMAB THERAPY FOR EXUDATIVE NEOVASCULAR AGE- RELATED MACULAR DEGENERATION (BEAT-AMD-STUDY). Schmid-Kubista KE, Krebs I, Gruenberger B, Schueller J, Binder S Annual ARVO Meeting , Fort Lauderdale, USA, Poster OXALIPLATIN, IRINOTECAN AND CETUXIMAB IN ADVANCED GASTRIC CANCER: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL (AGMT GASTRIC-2) E. Woell, R. Greil, W. Eisterer, M. Fridrik, B. Grünberger, K. Gattringer, B. Mayrbäurl, G. Russ, J. Thaler J Clin Oncology 26: 2008 (suppl, Abstract 15587) 53.EFFICACY RESULTS OF CETUXIMAB PLUS GEMCITABINE-OXALIPLATIN (GEMOX) IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA: A SINGLE CENTRE PHASE II STUDY. B. Gruenberger, J. Schueller, K. Kaczirek, M. Bergmann, W. Klose, M. Bischof, G. Schernthaner, T. Gruenberger J Clin Oncology 26: 2008 (suppl, Abstract 4568) 54.PROGRESSION-FREE SURVIVAL IN A PHASE II STUDY OF PERIOPERATIVE BEVACIZUMAB PLUS XELOX IN PATIENTS WITH POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER. T. Gruenberger, K. Kaczirek, M. Bergmann, C. C. Zielinski, B. Gruenberger J Clin Oncology 26: 2008 (suppl, Abstract 4073) 55.DOXORUBICIN PHARMACOKINETICS FOLLOWING TWO DIFFERENT LIPOSOMAL FORMULATIONS (CAELYX VS MYOCET) IN ADVANCED BREAST CANCER PATIENTS Schueller J, Czejka M, Krexner E, Aigner K, Gruenberger B

16 SABCS K-RAS STATUS AND RESPONSE IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA TREATED WITH CETUXIMAB PLUS GEMCITABINE-OXALIPLATIN (GEMOX): A SINGLE CENTER PHASE II STUDY B. Gruenberger, Schueller J, Tamandl D, Kaczirek K, Schernthaner G, Gruenberger T J Clin Oncology 27:15s, 2009 (suppl, Abstract 4586) 57.OXALIPLATIN, IRINOTECAN AND CETUXIMAB IN ADVANCED GASTRIC CANCER. FIRST EFFICACY RESULTS OF A MULTICENTER PHASE II TRIAL (AGMT GASTRIC-2) OF THE ARBEITSGEMEINSCHAFT MEDIKAMENTOESE TUMORTHERAPIE (AGMT). E. Woell, R. Greil, W. Eisterer, M. Fridrik, B. Grünberger, A. Zabernigg, B. Mayrbäurl, G. Russ, J. Thaler J Clin Oncology, 27:15s (2009) (suppl, Abstract 4538) 58.SECONDARY RESECTABILITY IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA TREATED WITH CETUXIMAB PLUS GEMCITABINE- OXALIPLATIN (GEMOX): A SINGLE CENTER PHASE II STUDY; B Grünberger, J. Schüller, D. Tamandl, K. Kaczirek, G. Schernthaner, T Grünberger; European Surgery 2009; 144/Suppl 230/09 59.SECONDARY RESECTABILITY IN PATIENTS WITH ADVANCED OR METASTATIC CHOLANGIOCARCINOMA TREATED WITH CETUXIMAB PLUS GEMCITABINE- OXALIPLATIN (GEMOX): A SINGLE CENTER PHASE II STUDY; B Grünberger, J. Schüller, D. Tamandl, K. Kaczirek, G. Schernthaner, T Grünberger; ACO-ASSO JAHRESTAGUNG, POSTER, , ST WOLFGANG 60.INFLUENCE OF CETUXIMAB APPLIED AS BIWEEKLY INFUSION ON THE PLASMA DISPOSITION OF CPT 11 AND ITS METABOLITES IN ADVANCED COLORECTAL CANCER J Schueller,.., B. Gruenberger Eco Esmo Berlin ASSOCIATION OF VEGF FEEDBACK PRODUCTION IN BEVACIZUMAB THERAPY WITH SYSTEMIC RESPONSE. P. Starlinger, T. Maier, D. Schauer, C. Nemeth, L. Alidzanovic, B. Gruenberger, T. Gruenberger, C. Brostjan J Clin Oncol 28:15s, 2010 (suppl; abstr 3056) 62.INFLUENCE OF THE K-RAS STATUS ON OUTCOME IN CHOLANGIOCARCINOMA. D. Niedersuess-Beke, T. Gruenberger, D. Tamandl, F. Wrba, H. Feichtinger, K. Kaczirek, J. G. Meran, B. Gruenberger J Clin Oncol 28, 2010 (suppl; abstr e21076) 63.PRE- AND POSTOPERATIVE CHEMOTHERAPY INCLUDING BEVACIZUMAB IN POTENTIALLY CURABLE METASTATIC COLORECTAL CANCER: A MULTICENTER, SINGLE-ARM PHASE II TRIAL RESULTS OF ASSO LM1. T. Gruenberger, F. Laengle, J. Thaler, W. Eisterer, D. Tamandl, B. Herberger, A. Lenauer, B. Gruenberger J Clin Oncol 28, 2010 (suppl; abstr e14032) 64.INFLUENCE OF THE K-RAS STATUS ON OUTCOME IN CHOLANGIOCARCINOMA.

17 Birgit Gruenberger, Dora Niedersuess-Beke, Dietmar Tamandl, Fritz Wrba, Klaus Kaczirek, Johannes Meran and Thomas Gruenberger World Congress of GI Cancer, Barcelona, July 2010, P TOLERABILITY OF NEOADJUVANT CHEMOTHERAPY WITH GEMCITABINE PLUS CISPLATIN IN ELDERLY (OLDER THAN AGE 65) PATIENTS (PTS) WITH MUSCLE-INVASIVE UROTHELIAL CANCER D. Niedersuess-Beke, B. Gruenberger, T. Puntus, W. Bauer, M. Lamche, P. Schramek, J. G. Meran J Clin Oncol 29: 2011 (suppl 7; abstr 296) 66.INFLUENCE OF KRAS STATUS OF COLORECTAL CANCER LIVER METASTASES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB PRIOR LIVER RESECTION Stefan Stremitzer, Judith Maresch, Thomas Aschacher, Brigitte Wolf, Fritz Wrba, Thomas Gruenberger, Birgit Gruenberger Frühjahrstagung ÖGHO, Pörtschach, Mai INFLUENCE OF KRAS STATUS OF COLORECTAL CANCER LIVER METASTASES IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY INCLUDING BEVACIZUMAB PRIOR LIVER RESECTION Stefan Stremitzer, Judith Maresch, Thomas Aschacher, Brigitte Wolf, Fritz Wrba, Thomas Gruenberger, Birgit Gruenberger Annual Meeting ASCO 2011, Chicago, June 2011 SONSTIGE ARBEITEN & FORTBILDUNGSVORTRÄGE 1. HEPATOTOXIZITÄT Schüll B, Scheithauer W Krebshilfe 4/02 2. MULTIMODALE LEBERMETASTASENTHERAPIE Schüll B, Scheithauer W, Grünberger T Chirurgie 4/02 3. ASCO NEWS: CHEMOTHERAPIE DES FORTGESCHRITTENEN KOLOREKTALKARZINOMS Grünberger B Jatros 9/05 4. PHASE II XELOX PLUS IRESSA Schüll B, Vortrag POST ASCO Update 2003, Salzburg Juni XELODA: DIE ORALE TUMORTHERAPIE: EMPFEHLUNGEN FÜR DIE PRAXIS Schüll B, Vortrag Das kolorektale Karzinom ASCO 2004 Update, Pöttsching, 4.Nov DERZEITIGE PALLIATIVE THERAPIEOPTIONEN BEIM METASTASIERTEN KOLOREKTALEN KARZINOM Schüll B, Vortrag

18 Fortbildungsveranstaltung Oberpullendorf, 13.Okt INNOVATIVE THERAPIEN BEIM KOLOREKTALKARZINOM: ADJUVANTE THERAPIE Fortbildungsveranstaltung Zwettl, 22.November THERAPIE DES KOLOREKTALKARZINOMS Fortbildungsveranstaltung Radstadt, 6.Jänner NEUE THERAPIEANSÄTZE BEIM METASTASIERTEN KOLONKARZINOM Fortbildungsveranstaltung Kaprun, März IST DAS METASTASIERTE KOLOREKTALE KARZINOM HEILBAR? 47. Österreichischer Chirurgenkongress, Juni INTERDISZIPLINÄREN MANAGEMENT VON LEBERTUMOREN UND LEBEROP WORKSHOP 2006, AKH-WIEN Kursleitung: Onkologische Sicht Grünberger B 12. AVASTIN anti VEGF COLORECTAL CANCER 5 th International Symposium on Cancer research and Therapy (Tokio, November 2006) 13. THERAPIE DES METASTASIERTEN KOLONKARZINOMS Fortbildungsveranstaltung Laa/Thaya, Dezember TARCEVA BEIM METASTASIERTEN PANKREASKARZINOM: PRAKTISCHE ASPEKTE UND NEBENWIRKUNGSMANAGEMENT Fortbildungsveranstaltung, Wien, März THERAPIE DES METASTASIERTEN KOLOREKTALKARZINOM EIN ÜBERBLICK Interdisziplinäres Symposium, Wien, Mai DAS METASTASIERTE CRC INNOVATIVE THERAPIEN AUS ONKOLOGISCHER SICHT Fortbildungsveranstaltung, Oberwart, Oktober NEOADJUVANTE CHEMOTHERAPIE BEI KOLOREKTALEN LEBERMETASTASEN Grünberger B Krebshilfe, Heft 1/ HÄUFIGE TUMOREN II - MAMMAKARZINOM (DIABETESSPEZIFISCHE ÄTIOLOGIE, FRÜHERKENNUNG, INTERDISZIPLINÄRES MANAGEMENT) Grünberger B

19 Diabetes Forum, 2/ NEOADJUVANTE CHEMOTHERAPIE BEI KOLOREKTALEN LEBERMETASTASEN Workshop Deliver Excellence, Wien, September THERAPIE DES METASTASIERTEN KOLOREKTALKARZINOMS EIN UPDATE CNM Symposium, 17.Sep 2009, Kaiserpavillon 21. RATIONALE DER NEOADJUVANTEN THERAPIE UND LEVEL I EVIDENCE BEI KOLOREKTALEN LEBERMETASTASEN Individualisierte Krebstherapie, Aco-Asso Jahrestagung, , St Wolfgang 22. G-LUCAS TRIAL CRCR-Experten-Meeting K-ras and Beyond, Wien, EXPERTENFORUM XELODA IM ADJUVANTEN SETTING Grünberger B, Teilnahme Wien, EXPERTENMEETING: NEUES THERAPIE-KONZEPT BEI MALIGNEN ASZITES Grünberger B, Teilnahme Wien, SYSTEMISCHE THERAPIE DES NIERENZELLKARZINOMS 5.Urologisch-Onkologisches Symposium, BHB Wien, UPDATE MCRC 2010 RECENT DEVELOPMENTS 3.VEGF SYMPOSIUM, Mayerling, G-LUCAS TRIAL ABCSG-Meeting Saalfelden, ÜBERBLICK ZUR PALLIATIVEN THERAPIE DES KOLOREKTALKARZINOMS Grünberger B Krebshilfe Heft 5: SYSTEMISCHE CHEMOTHERAPIE CHOLANGIOCELLULÄRES KARZINOM ÖGGH Gastrroenterologische onkologische Diskussion Cholangiocelluläres Karzinom , Wien 30. MALIGNE TUMOREN DER GALLENBLASE / GALLENGÄNGE DESO Kurs, Diagnostik und Therapie von Patienten/innen mit gastrointestinalen Tumoren Mai 2011 Innsbruck